bradykinin B2 antagonist
Icatibant
Answer
Icatibant is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 3 (3 phase 3 trials, 0 with posted results). It has 37 registered trials, 2 of them running. Brand names on the FDA label register: Sajazir, Icatibant and Firazyr.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
37 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 13 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 19 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Icatibant changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 37 trials
| NCT04113109 | Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 completed · register updated 2026-08-11 |
|---|---|
| NCT05509569 | A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema completed · register updated 2026-08-07 |
| 2024-516247-62-00 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucricti no status recorded · register updated 2026-07-17 |
| 2023-505766-28-00 | A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hered no status recorded · register updated 2026-06-01 |
| NCT05834777 | Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor currently recruiting participants · register updated 2026-04-15 |
| NCT04488081 | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients running, but no longer enrolling · register updated 2026-03-16 |
| NCT06346899 | A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China completed · register updated 2026-01-21 |
| NCT07009262 | A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks completed · register updated 2026-01-13 |
| NCT07290855 | A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema completed · register updated 2025-12-18 |
| 2023-507268-37-00 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Oral Deucrictibant Soft Capsule for On-Demand Treatmen no status recorded · register updated 2025-09-16 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.